Dengue is a mosquito-borne viral infection which causes severe flu-like illness and, sometimes cause lethal complications. According to World Health Organization, ‘The incidence of dengue has increased 30-fold over the last 50 years. Up to 50-100 million infections are now estimated to occur annually in over 100 endemic countries, putting almost half of the world’s population at risk’. Currently, there is only one dengue virus vaccine that is approved. In May 2019, U.S. Food and Drug Administration (FDA), approved Dengvaxia, manufactured by Sanofi Pasteur in United States for use in children 9-16 years. The vaccine can only be given to children and teens who have had one previous laboratory-confirmed case of dengue. Dengvaxia is licensed for use in 19 countries, plus the eligible parts of the European Union and currently available in 10 countries in Latin America and Asia.

The factors playing a pivotal role in driving the market include increasing prevalence of dengue infection globally, favorable government initiatives and increasing research & development activities for the development of dengue vaccine.

Some of the key players operating in the market include Sanofi, Panacea Biotec Ltd., Biological E, GlaxoSmithKline plc and Takeda Pharmaceutical Company Limited among others.

To gather deep-rooted insights with respect to market dynamics, competitive landscape and to unlock the market potential of dengue vaccines, subscribe to the report by clicking and filling up the ‘Pre-book’ section.